Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB268 in locally advanced or metastatic breast cancer (Phase Ib/II)
ChiCTR2600129246Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GB268 in breast cancer and triple-negative breast cancer (TNBC) (7 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective Response Rate and DLT incidence rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
GB268
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600129246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129246.